RxDoctor Payments Data

Kristen White, APRN

Family · San Antonio, TXNPI 1811395320

Payments from drug & device makers

$1,894in general payments, 2019–2025

Across 64 payments — averaging $29.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$286
  • Medtronic$276
  • Axonics, Inc.$213
  • Merck$205
  • Novartis$198
  • Sumitomo Pharma America, Inc.$187
  • plus $530 from 13 others

What the payments were for

  • Food & beverage$1,85998%
  • Education$352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,894 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$127,511
Medicare patients
465
Services billed
5,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron82$76,250
MyrbetriqMirabegron74$57,032
Silodosin36$2,853
Estradiol28$2,785
Fosfomycin Tromethamine13$1,811
Tamsulosin Hcl136$1,724
Trimethoprim26$1,660
NitrofurantoinNitrofurantoin Macrocrystal23$1,659
Solifenacin Succinate51$1,618
Trospium Chloride19$1,037
Finasteride43$958
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst54$858
Cephalexin45$712
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav65$679
Alfuzosin Hcl ErAlfuzosin Hcl16$642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$187$76,25082 claims
Astellas Pharma US IncMyrbetriq$17$57,03274 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →